An experimental small-molecule inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase), studied in preclinical mouse and cell work for effects on fat and metabolism. It is not a peptide and has essentially no human trial data.
Reviewed for accuracy · Last reviewed July 8, 20265-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule that inhibits nicotinamide N-methyltransferase, or NNMT, an enzyme involved in cellular methylation and NAD+ handling. In preclinical studies, blocking NNMT in fat tissue lowered a metabolite called 1-MNA and raised intracellular NAD+ and SAM, which researchers link to reduced fat storage in adipocytes. It is worth stressing that this is a laboratory mechanism, not a demonstrated human effect.
The reported metabolic and fat-loss findings come entirely from mouse and cell studies. There are no known human clinical trials of 5-Amino-1MQ, it is not FDA-approved, and it is not a peptide despite often being grouped with research peptides. Treat it as an adjacent experimental research compound whose relevance to people is unproven.
There is no established human dose for 5-Amino-1MQ. Preclinical studies dosed mice, not people, and no human trials were found. Oral capsule figures seen online are anecdotal and unvalidated.
Read the full 5-Amino-1MQ dosage guide →A human safety profile for 5-Amino-1MQ is essentially uncharacterized. Preclinical mouse work reported no obvious adverse effects at studied doses, but that does not establish human safety.
Read the full 5-Amino-1MQ side effects guide →Handling and storage guidance for 5-Amino-1MQ is not standardized because it is an unapproved research chemical. Follow supplier documentation and general lab-chemical precautions. See the full storage & safety guide for general handling and disposal basics.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.